Cardiff Oncology (CRDF) Expected to Announce Quarterly Earnings on Thursday

Cardiff Oncology (NASDAQ:CRDF) is expected to be issuing its Q1 2025 quarterly earnings data before the market opens on Thursday, May 1st. Analysts expect the company to announce earnings of ($0.20) per share and revenue of $0.09 million for the quarter.

Cardiff Oncology Stock Performance

NASDAQ CRDF opened at $2.95 on Tuesday. The business’s 50 day moving average price is $3.43 and its 200-day moving average price is $3.48. Cardiff Oncology has a fifty-two week low of $2.01 and a fifty-two week high of $5.64. The company has a market cap of $196.25 million, a P/E ratio of -3.14 and a beta of 1.74.

Analysts Set New Price Targets

Separately, HC Wainwright raised their price target on shares of Cardiff Oncology from $13.00 to $17.00 and gave the stock a “buy” rating in a research note on Friday, February 28th.

Cardiff Oncology Company Profile

Cardiff Oncology, Inc, a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.